Mediators of Inflammation / 2012 / Article / Tab 1

Research Article

Circulating Cytokines and Growth Factors in Pediatric Pulmonary Hypertension

Table 1

Patient demographics and clinical measurements.

Patient demographics (no of subjects = 70)

Female—no. (%)37 (52.9%)
APAH—no. (%)45 (64.3%)
 Congential heart disease31 (44.3%)
 Chronic lung disease11 (15.7%)
 Clotting disorders10 (14.3%)
Age (years)—median (IQR)8.0 (4.4–13.0)
Therapies
 Mono therapy23 (32.9%)
 Dual therapy23 (32.9%)
 Triple therapy10 (14.3%)
 Calcium channel blockers 22 (31.4%)
 PDE-5 inhibitors29 (41.4%)
 Endothelin receptor blockers 25 (35.7%)
 Prostacyclin 23 (32.9%)
  Epoprostenol 12 (17.1%)
  IV Treprostinil 8 (11.4%)
  Inh Iloprost 3 (4.3%)
CATH variables—median (IQR) (n = 59)
 Pulmonary artery pressure, mm Hg34 (23–56)
 Pulmonary capillary wedge pressure,  mm Hg8 (6–10)
 Right atrial pressure, mm Hg5 (3–7)
 Cardiac index, L/min × m23.5 (3.0–4.3)
 Pulmonary vascular resistance index,  wood units × m25.6 (4.1–13.9)
 PVR/SVR0.48 (0.27–0.76)
 Vasoreactivity (% change in mPAP  w/NO)−21.1 (−29.5 to −12.8)
Follow-up time (months)—median (min–max)36 (12–89)
Adverse outcomes16 (22.9%)
 Within 12 months9 (12.9%)
 First observed outcome
 Expired10
 Transplantation0
 Initiation of IV prostanoids8